NEXIGN
26.10.2021 09:02:17 CEST | Business Wire | Press release
Nexign (part of ICS Holding), an international provider of business support systems (BSS), has announced it won the MEA Technology Achievement Award and was shortlisted for another prestigious international award for the telecom industry, Glotel .
The MEA Tech Award was introduced by the MEA Business magazine, one of the business's top publications in the Middle East and Africa, while the Global Telecom Award brings together the top players in telecom from around the world recognizing innovation and excellence.
The prize and the nomination were awarded the same week for the Nexign Microservices Platform and the Microservices Factory project based on it.
Nexign Microservices Platform supports the whole cycle of development and delivery based on cloud-native microservices architecture, which lays the foundation for continuous creation of new digital services. The framework leverages CI/CD automation and facilitates partner collaboration through standardised APIs. This solution enabled the launch of Microservices Factory at MegaFon and allowed the company to reduce TTM for internal innovations. Nexign Microservices Framework empowered MegaFon to roll out 100+ new services, bring to market a multi-subscription digital services platform MegaFon Plus, and generally slash TTM from 3-4 months up to 2 weeks.
The project resulted in building the Open Ecosystem, constantly expanding with the new partners enriching MegaFon’s portfolio with the new product offerings. Nexign Microservices Platform enables telecom operators to always stay at the forefront of market changes and steadily cater to the ever-changing needs of its customers.
Both the development project and the final product have garnered recognition from the international telecom industry, to which the MEA Tech Award and the Glotel nomination are a token.
“The award and the nomination are not just a huge honour for Nexign. They signify the professional community’s recognition and appreciation of our projects. We strongly believe the Microservices Platform is a solution the world of telecom really needs these days. It would allow CSPs to swiftly react to any challenges the market can throw at them,” says Dmitry Antipov, the Customer Relations Director at Nexign.
About Nexign
Nexign (a part of Intellectual Computer Systems Holding (ICS Holding) is a major supplier of BSS solutions for telecom operators across 17 countries. The company focuses on modernising CSP’s IT systems to boost their profitability and slash TTM for new products.
Over 30 years on the market, Nexign has created an extensive suite of technological solutions to support and sustain transformation of telecom operators. Nexign’s products range from convergent BSS systems to elaborate optimisation solutions for subordinate software. Nexign boasts its comprehensive approach to reorganising all kinds of processes in the telecom industry, which offers a fresh impetus to the customer business and encourages innovations.
For more information, please visit the website and follow the latest news from Nexign on Twitter , Facebook and LinkedIn .
About ICS Holding
Intellectual Computer Systems Holding (https://x-holding.ru/ ) is a multidisciplinary Russian IT group, which holds a leading position in the technology and IT services development market. ICS Holding is the largest IT provider for telecom operators and one of the fastest growing IT holdings in the Russian market. ICS Holding is among Russia’s top three largest IT development companies, top ten IT companies and top ten suppliers of equipment for the industrial sector. The holding brings together more than 30 companies united in five subholdings: YADRO, Nexign, Citadel, Kryptonit and Forpost.
ICS Holding’s top priorities include the digital transformation of enterprise companies, information security, data storage systems, cryptography and quantum computing, machine learning and artificial neural networks, blockchain technology and artificial intelligence (AI). In terms of geographical reach, the business covers all regions of Russia, as well as several countries in the CIS and further afield.
ICS Holding companies employ in excess of 6,000 people. More than 120 global projects have been implemented in Russia and worldwide. More than 1000 of ICS Holding’s customers work in more than 20 countries.
The total revenue of ICS Holding companies in 2020 reached 85 billion rubles. The partner network of ICS Holding includes more than 50 companies in Russia and beyond.
15.09.2020 ICS Holding became a part of USM Telecom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005212/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom